NCI Experimental Therapeutics Chemical Biology Consortium

Pre-Solicitation Announcement

In 2009, the National Cancer Institute (NCI) initiated the Chemical Biology Consortium to help translate promising scientific discoveries into tomorrow’s anticancer therapeutics.

Members of the Chemical Biology Consortium (CBC) collaborate on project teams to discover hits, advance them into leads and optimize leads to assess efficacy in animal models of cancer. Support from NCI enables concepts and therapeutic hypotheses to be advanced that otherwise might not be supported by commercial entities or private investment. The scientific expertise and technical capabilities in the CBC are assembled from a diverse collection of public and private research institutions as well as for-profit entities.

Leidos Biomedical Research, Inc. has issued a Request for Proposal (RFP) that will initiate the application process. Interested parties are encouraged to review the recent RFP announcement at SAM.gov

For any questions related to the Chemical Biology Consortium OR to request a copy of RFP S22-015, please use the email address below:
cbcbproposals@mail.nih.gov